Skip to main content
Clinical Trials/ACTRN12614000496617
ACTRN12614000496617
Active, not recruiting
Phase 4

Study of audiometry, speech reception threshold, retinal vasculature, inflammatory marker and neurocognitive effects of aspirin in age-related hearing loss to determine the effects of daily low-dose aspirin 100mg versus placebo on hearing outcomes in the setting of in healthy older adults aged 70 years and over

Monash University0 sites1,262 target enrollmentMay 12, 2014

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Age-related hearing loss
Sponsor
Monash University
Enrollment
1262
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 12, 2014
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Enrolments into the ASPREE parent study, aged 70 years and over who are able and willing to provide informed consent

Exclusion Criteria

  • History of a diagnosed cardiovascular event, including AMI and stroke, atrial fibrillation, serious intercurrent illness likely to cause death within 5 years, cognitive impairment or dementia, disability, anaemia, a current or recurrent condition with a high risk of major bleeding, absolute contraindication or allergy to aspirin.
  • Specific exclusion criteria for participation in ASPREE\-HEARING include the presence of bilateral Lyric or internal hearing aids or bilateral cochlear imnplants.

Outcomes

Primary Outcomes

Not specified

Similar Trials